Network Pharmacological Study on Guizhi Fuling Pills in the Treatment of Mammary Gland Hyperplasia

doi:10.19803/j.1672-8629.2019.11.01

Abstract

Abstract: Objective To study the mechanism of Guizhi Fuling pills against mammary glandhyperplasia using network pharmacological methods. Methods TCMSP, Drugbank and TTD databases were searched for the target proteins of mammary gland hyperplasia. The Uniprot database was used to query the corresponding gene names of target proteins and select human proteins to obtain the target proteins of mammary gland hyperplasia regulated by Guizhi Fuling pills. TCMSP software was used to search the target proteins of breast hyperplasia. The active ingredients of Guizhi Fuling pills and their corresponding targets were obtained. Cytoscape 3.2.1 software was used to construct the target network of active ingredients of Guizhi Fuling pills and conduct topological analysis of the network. Gene ontology (GO) enrichment analysis and genome encyclopedia (Kyoto Encyclopedia of Genes and Genomes, KEGG) pathway analysis of key targets were carried out using the STRING database and DAVID database. Results Network pharmacological studies suggested that Guizhi Fuling pills might inhibit breast hyperplasia through inflammatory signaling pathways and hormonal signaling pathways. Guizhi Fuling pills had the multi-component and multi-target advantages in the treatment of mammary gland hyperplasia. Conclusion The active ingredients and mechanism of Guizhi Fuling pills in the treatment of mammary gland hyperplasia have been studied with network pharmacologicalMethods, which can help find out more about its mechanism.

Key words: Guizhi Fuling pills, mammary gland hyperplasia, network pharmacology

CLC Number:

R968

SHI Wei, LV Zhongmin, ZHANG Haiming, NIE Yinglan, SUN Jian. Network Pharmacological Study on Guizhi Fuling Pills in the Treatment of Mammary Gland Hyperplasia[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 641-648.

References

[1] 刘艳芳,刘艳芹,杨倩.中药内服在治疗乳腺增生患者中的应用及护理分析[J].实用妇科内分泌电子杂志, 2018,5(36):30.
[2] 丘平.乳腺增生中医外治疗法研究进展[J].云南中医中药杂志 2018, 39(2)：85-88.
[3] 李晓庆.桂枝茯苓汤加减结合通络法治疗卵巢囊肿的临床疗效分析[J].世界复合医学, 2019, 5(6):54-56，60.
[4] 刘文博.桂枝茯苓丸辅助治疗子宫肌瘤的可行性及对激素水平、血液流变学的影响[J].海峡药学, 2019, 31(5):167-169.
[5] 陈云,李志强,毛丽,等.桂枝茯苓丸对气滞血瘀型慢性盆腔炎患者症状、超声及血液流变学的影响[J].光明中医, 2019, 34(9):1316-1319.
[6] 宋洁.分析桂枝茯苓汤加味治疗乳腺增生的临床疗效[J].世界最新医学信息文摘, 2018, 18(56):178.
[7] 杨秀清.桂枝茯苓胶囊治疗女性乳腺囊性增生病的疗效观察[J].中国医药指南, 2013, 11 (32) :512.
[8] 杨丹,孙春艳.应用桂枝茯苓胶囊与维生素E治疗乳腺增生的疗效分析[J].实用妇科内分泌杂志(电子版), 2016,3(11):154-155.
[9] 才旦多杰,赵海宁,施志军.桂枝茯苓丸辅助治疗乳腺增生的疗效及安全性观察[J].山东医药, 2016, 56(34):68-70.
[10] 朱萱萱,张忠华,邱召娟,等.桂枝茯苓胶囊治疗乳腺增生大鼠的实验研究[J].现代中西医结合杂志, 2006,15(5):571-572, 576.
[11] 努尔比耶•买买提吐尔逊，唐努尔•阿布力米提.更年期女性乳腺增生患者激素水平特点[J].世界最新医学信息文摘, 2019, 44（19）：68.
[12] Sciascia Q , Sales F , Vand L D , et al. Nutritional plane oftwin-bearing ewes alters fetal mammary gland biochemicalcomposition and mTOR/MAPK pathway signaling[J].J AnimSci，2015,93(2): 699-708.
[13] Wang Y , Wei S , Gao T, et al. Anti-Inflammatory effect ofa TCM formula Li-Ru-Kang in rats with hyperplasia ofmammary gland and the underlying biological mechanisms[J].Front Pharmacol,2018,9（11）: 1318.
[14] Chmielewska M , Skibińska I, Kotwicka M, et al. Mitochondria:Target organelles for estrogen action[J]. Postepy Hig Med Dosw, 2017, 71(1): 454-465.
[15] Tohyama S , Miyagawa S , Lange A , et al. Understandingthe molecular basis for differences in responses of fish estrogen receptor subtypes to environmental estrogens[J]. EnvironSci Technol, 2015,49(12): 7439-7447.
[16] Fung, T S, Liu D X .Activation of the c-Jun NH2-terminalkinase pathway by coronavirus infectious bronchitis virus promotes apoptosis independently of c-Jun[J]. Cell DeathDis, 2017,8(12): 3215.
[17]常秀娟,周军,张帅,等.桂枝茯苓胶囊对乳腺增生大鼠性激素水平和乳腺组织的影响[J].中国中药志, 2014, 39(21):4139.
[18]周小祝,莫志贤.桂枝茯苓丸的药理作用研究进展[J].医药导报, 2006, 25(2):142-143.
[19]王景诗,梁罟.乳腺增生症与心理、精神因素关系的回顾性分析[J].黑龙江医学, 2015, 39(9):1043-1044. 